Dren Bio is a privately held, biopharmaceutical company focused on developing therapeutic antibodies for the treatment of cancer, autoimmune and other serious diseases. The Company’s management team and scientific advisors have significant expertise covering the discovery and development of engineered antibodies designed to selectively target and deplete pathologic cells, protein aggregates and other disease-causing agents. At Dren we selectively engage an effector cell for targeted depletion of diseased cells or agents. Our pipeline is currently comprised of two distinct drug discovery programs.